Early transduction produces highly functional chimeric antigen receptor-modified virus-specific T-cells with central memory markers: a Production Assistant for Cell Therapy (PACT) translational application

[1]  Pei Zhi Cheryl Chia,et al.  TGFβ in T cell biology and tumor immunity: Angel or devil? , 2014, Cytokine & growth factor reviews.

[2]  Malcolm K. Brenner,et al.  Activity of Broad-Spectrum T Cells as Treatment for AdV, EBV, CMV, BKV, and HHV6 Infections after HSCT , 2014, Science Translational Medicine.

[3]  Carlos A Ramos,et al.  CD19-CAR Trials , 2014, Cancer journal.

[4]  H. Heslop,et al.  T-cell therapy for viral infections. , 2013, Hematology. American Society of Hematology. Education Program.

[5]  U. Gerdemann,et al.  Safety and clinical efficacy of rapidly-generated trivirus-directed T cells as treatment for adenovirus, EBV, and CMV infections after allogeneic hematopoietic stem cell transplant. , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

[6]  C. Cruz,et al.  Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study. , 2013, Blood.

[7]  E. Mischak-Weissinger,et al.  CMV-, EBV- and ADV-specific T cell immunity: screening and monitoring of potential third-party donors to improve post-transplantation outcome. , 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[8]  S. Pai,et al.  Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation. , 2013, Blood.

[9]  U. Gerdemann,et al.  Rapidly Generated Multivirus-specific Cytotoxic T Lymphocytes for the Prophylaxis and Treatment of Viral Infections , 2012, Molecular Therapy.

[10]  W. Wilson,et al.  B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. , 2012, Blood.

[11]  Martin Pule,et al.  Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. , 2011, Blood.

[12]  Michel Sadelain,et al.  Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. , 2011, Blood.

[13]  David L. Porter,et al.  T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia , 2011, Science Translational Medicine.

[14]  S. Riddell,et al.  Engraftment of human central memory-derived effector CD8+ T cells in immunodeficient mice. , 2011, Blood.

[15]  Hao Liu,et al.  Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma , 2008, Nature Medicine.

[16]  H. Heslop,et al.  Exploiting Cytokine Secretion to Rapidly Produce Multivirus-specific T Cells for Adoptive Immunotherapy , 2008, Journal of immunotherapy.

[17]  Mike Gough,et al.  Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates. , 2008, The Journal of clinical investigation.

[18]  Chung-Che Chang,et al.  Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals , 2006, Nature Medicine.

[19]  T. Lion,et al.  Safe adoptive transfer of virus‐specific T‐cell immunity for the treatment of systemic adenovirus infection after allogeneic stem cell transplantation , 2006, British journal of haematology.

[20]  C. Rooney,et al.  Target Antigen Expression on a Professional Antigen-Presenting Cell Induces Superior Proliferative Antitumor T-Cell Responses via Chimeric T-Cell Receptors , 2006, Journal of immunotherapy.

[21]  C. Rooney,et al.  Fiber-modified adenoviruses generate subgroup cross-reactive, adenovirus-specific cytotoxic T lymphocytes for therapeutic applications. , 2004, Blood.

[22]  J. Cheville,et al.  B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma. , 2003, Cancer research.

[23]  C. Rooney,et al.  Epstein-Barr virus-specific human T lymphocytes expressing antitumor chimeric T-cell receptors: potential for improved immunotherapy. , 2002, Blood.

[24]  D. Zwick.  Children ’ s Mercy Hospitals and Clinics Pathology and Laboratory Medicine Newsletter March 2003 News From Hemotology , 2002 .

[25]  C. Bollard,et al.  Targeting of GD2‐positive tumor cells by human T lymphocytes engineered to express chimeric T‐cell receptor genes , 2001, International journal of cancer.

[26]  G. Freeman,et al.  Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation , 2000, The Journal of experimental medicine.

[27]  D. Srivastava,et al.  Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. , 1998, Blood.

[28]  C. Rooney,et al.  Extensive cross-reactivity of adenovirus-specific cytotoxic T cells. , 1998, Human gene therapy.

[29]  S Kimbrough,et al.  Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the treatment of patients with EBV-positive relapsed Hodgkin's disease. , 1998, Blood.

[30]  H. Heslop,et al.  Production of genetically modified Epstein-Barr virus-specific cytotoxic T cells for adoptive transfer to patients at high risk of EBV-associated lymphoproliferative disease. , 1995, Journal of hematotherapy.